Table 2 The clinical characteristics of low-risk postmolar GTN
Variables* | Control (n = 72) | P-chem (n = 24) | P value |
|---|---|---|---|
Interval from HM to GTN (days) | 44 (11–2555) | 69 (14–300) | 0.001 |
Largest dimension of tumor (cm) | |||
< 3 | 40 (56%) | 4 (17%) | 0.181 |
≥ 3 | 23 (32%) | 6 (25%) | |
Number of metastases | 0 (0–9) | 0 (0–9) | 0.054 |
hCG before first-line chemotherapy (IU/L) | 4503.5 (5.3–514,972.0) | 415.8 (10.7–44,808.0) | 0.000 |
FIGO stage | |||
I | 22 (31%) | 11 (46%) | 0.414 |
II | 1 (1%) | 0 (0%) | |
III | 49 (68%) | 13 (54%) | |
WHO risk score | 2 (0–6) | 2 (0–6) | 0.208 |
First-line chemotherapy agent | |||
Methotrexate | 69 (96%) | 13 (54%) | 0.000 |
Actinomycin D | 3 (4%) | 8 (33%) | |
5-Fluorouracil | 0 (0%) | 3 (13%) | |
Resistant to first-line drug | 29 (40%) | 10 (42%) | 0.904 |
Resistant to first-line MTX | 26 (38%) | 5 (38%) | 0.066 |
Resistant to second-line drug | 6 (21%) | 2 (20%) | 1.000 |
Resistant to single-agent drug | 8 (11%) | 4 (17%) | 0.487 |
Chemotherapy cycles to hCG normalization | 4 (1–9) | 3 (1–7) | 0.157 |
Total chemotherapy cycles | 6 (1–12) | 6 (3–11) | 0.508 |